Top

Published in:

01-07-2014 | Review Article

Anticonvulsant drugs and hematological disease

Authors: A. Verrotti, A. Scaparrotta, S. Grosso, F. Chiarelli, G. Coppola

Published in: Neurological Sciences | Issue 7/2014

Abstract

Many antiepileptic drugs (AEDs) are associated with hematological disorders that range from mild thrombocytopenia or neutropenia to anemia, red cell aplasia, until bone marrow failure. Fortunately, potentially fatal hematological disorders such as aplastic anemia are very rare. This review investigates hematological effects associated with classic and newer AEDs: a PubMed search indexed for MEDLINE was undertaken to identify studies in adults, children and animals using the name of all anticonvulsant drugs combined with the terms “hematological disease” and “hematological abnormalities” as key words. The most common hematological alterations occur with older AEDs than newer. Indeed, careful hematological monitoring is needed especially using carbamazepine, phenytoin and valproic acid. The pathogenetic mechanisms are still unknown: they seem to be related to an immunological mechanism, but drugs pharmacokinetics and pharmacodynamics interactions may also play an important role. Further research is needed to assess the real pathogenetic mechanism at the basis of hematological complications caused by AEDs.

Asadi-Pooya AA, Sperling MR (2009) Antiepileptic drugs and hematological disorders. Antiepileptic drugs: a clinician’s manual. Oxford University Press, New York, pp 165–170

Verrotti A, Coppola G, Parisi P et al (2010) Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 112:1–10PubMed

Asadi-Pooya AA, Sperling MR (2009) Mechanisms of actions and pharmacokinetic properties of antiepileptic drugs. Antiepileptic drugs: a clinician’s manual. Oxford University Press, New York, pp 69–148

Conti L, Gandolfo GM (1983) Benzodiazepine-induced thrombocytopenia. Demonstration of drug-dependent platelet antibodies in two cases. Acta Haematol 70:386–388PubMed

El-Sayed S, Symonds RP (1988) Lorazepam induced pancytopenia. Brit Med J 296:1332

Bautista-Quach MA, Liao YM, Hsueh CT (2010) Pancytopenia associated with clonazepam. J Hematol Oncol 3:24PubMedCentralPubMed

Veall RM, Hogarth HC (1975) Thrombocytopenia during treatment with clonazepam. Br Med J 4:462PubMedCentralPubMed

Bussien R (1974) Acute granulocytopenia after simultaneous administration of gentamicin and diazepam. Nouv Presse Med 3:1236PubMed

Baumes RM (1971) Drug induced cytopenia: acute thrombopenic purpura and active antiplatelet antibodies in the presence of valium. Maroc Med 546:321–324PubMed

10.

Ishikita T, Ishiguro A, Fujisawa K et al (1999) Carbamazepine-induced thrombocytopenia defined by a challenge test. Am J Hematol 62:52–55PubMed

11.

Handoko KB, Souverein PC, van Staa TP et al (2006) Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 47:1232–1236PubMed

12.

Kaufman DWKJ, Levy M, Shapiro S (1991) The drug etiology of agranulocytosis and aplastic anemia. Oxford University Press, New York

13.

Blackburn SC, Oliart AD, Garcia Rodriguez LA et al (1998) Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 18:1277–1283PubMed

14.

Yamamoto M, Suzuki N, Hatakeyama N et al (2007) Carbamazepine-induced hemolytic and aplastic crises associated with reduced glutathione peroxidase activity of erythrocytes. Int J Hematol 86:325–328PubMed

15.

Tagawa T, Sumi K, Uno R et al (1997) Pure red cell aplasia during carbamazepine monotherapy. Brain Dev 19:300–302PubMed

16.

Chandra Sekhar C, Ramana Reddi V, Srinivas B, Naik KR (1998) Pure red cell aplasia associated with carbamazepine. J Assoc Physicians India 46:655–656PubMed

17.

Fraile G, Sánchez D, Achecar L, Ferrere F (2008) Pure red cell aplasia secondary to carbamazepine. Rev Clin Esp 208:533–534PubMed

18.

Tohen M, Castillo J, Cole JO et al (1991) Thrombocytopenia associated with carbamazepine: a case series. J Clin Psychiatry 52:496–498PubMed

19.

Gordon MA (1992) Carbamazepine-associated thrombocytopenia. J Clin Psychiatry 53:378–379PubMed

20.

Terao T (1993) Transient thrombocytopenia while continuing carbamazepine. Am J Psychiatry 150:1750–1751PubMed

21.

Drury I, Vanderzant CW (1988) Carbamazepine-induced isolated thrombocytopenia. Am J Psychiatry 145:1034PubMed

22.

Kaneko K, Igarashi J, Suzuki Y et al (1993) Carbamazepine-induced thrombocytopenia and leucopenia complicated by Henoch–Schonlein purpura symptoms. Eur J Pediatr 152:769–770PubMed

23.

Konishi T, Naganuma Y, Hongo K et al (1993) Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 152:605–608PubMed

24.

Aster RH, Bougie DW (2007) Drug-induced immune thrombocytopenia. N Engl J Med 357:580–587PubMed

25.

Taher AT, Arabi M, Sibai H et al (2012) Carbamazepine-induced thrombocytopenia. Blood Cells Mol Dis 48:197–198PubMed

26.

George JN, Raskob GE, Shah SR et al (1998) Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129:886–890PubMed

27.

Royer D, George JN, Terrel DR (2011) Drug-induced thrombocytopenia. http://www.ouhsc.edu/platelets/ditp.html

28.

Kimura M, Yoshino K, Maeoka Y, Suzuki N (1995) Carbamazepine-induced thrombocytopenia and carbamazepine-10,11-epoxide: a case report. Psychiatry Clin Neurosci 49:69–70PubMed

29.

Goraya JS, Virdi VS (2003) Carbamazepine-induced immune thrombocytopenia. Neurol India 51:132–133PubMed

30.

Owens CW, Parker NE, Nunn PP, Davies J (1980) Agranulocytosis associated with carbamazepine, and a positive reaction with anti-lymphoid leukaemia antiserum during recovery. Postgrad Med J 56:665–668PubMedCentralPubMed

31.

Banfi L, Ceppi M, Colzani M et al (1998) Carbamazepine-induced agranulocytosis. Apropos of 2 cases. Recenti Prog Med 89:510–513PubMed

32.

Cambon S, Rossi P, Miliani Y et al (1999) Severe agranulocytosis induced by carbamazepine (Tegretol). Ann Fr Anesth Reanim 18:542–546PubMed

33.

Olcay L, Pekcan S, Yalnizoğlu D et al (1995) Fatal agranulocytosis developed in the course of carbamazepine therapy. A case report and review of the literature. Turk J Pediatr 37:73–77PubMed

34.

Luchins DJ (1984) Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. Am J Psychiatry 141:687–688PubMed

35.

Tohen M, Castillo J, Baldessarini RJ et al (1995) Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 152:413–418PubMed

36.

Cates M, Powers R (1998) Concomitant rash and blood dyscrasias in geriatric psychiatry patients treated with carbamazepine. Ann Pharmacother 32:884–887PubMed

37.

Bertolino JG (1990) Carbamazepine. What physicians should know about its hematologic effects. Postgrad Med 88:183–186PubMed

38.

Sobotka JL, Alexander B, Cook BL (1990) A review of carbamazepine’s hematologic reactions and monitoring recommendations. DICP 24:1214–1219PubMed

39.

Asadi-Pooya AA, Ghetmiri E (2006) Folic acid supplementation reduces the development of some blood cell abnormalities in children receiving carbamazepine. Epilepsy Behav 8:228–231PubMed

40.

Massey GV, Dunn NL, Heckel JL et al (1994) Aplastic anemia following therapy for absence seizures with ethosuximide. Pediatr Neurol 11:59–61PubMed

41.

Seip M (1983) Aplastic anemia during ethosuximide medication. Treatment with bolus-methylprednisolone. Acta Paediatr Scand 72:927–929PubMed

42.

Imai T, Okada H, Nanba M et al (2003) Ethosuximide induced agranulocytosis. Brain Dev 27:522–524

43.

Steinweg DL, Bentley ML (2005) Seizures following reduction in phenytoin level after orally administered folic acid. Neurology 64:1982PubMed

44.

Alehan FK, Russell EC, Pellock JM (1999) Phenytoin-associated thrombocytopenia in a toddler. J Child Neurol 14:130–131PubMed

45.

Ranzino AM, Sorrells KR, Manor SM (2010) Possible acute thrombocytopenia post esomeprazole and hydantoin coadministration. J Pharm Pract 23:140–143PubMed

46.

Sharafuddin MJ, Spanheimer RG, McClune GL (1991) Phenytoin-induced agranulocytosis: a nonimmunologic idiosyncratic reaction? Acta Haematol 86:212–213PubMed

47.

Taetle R, Lane TA, Mendelsohn J (1979) Drug-induced agranulocytosis: in vitro evidence for immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody. Blood 54:501–512PubMed

48.

Tanaka S, Toujou H, Tara M, Uetsuhara K (2000) Diphenylhydantoin-induced pure red cell aplasia after neurological surgery: report of two cases. No Shinkei Geka 28:713–717PubMed

49.

Yunis AA, Arimura GK, Lutcher CL et al (1967) Biochemical lesion in dilantin-induced erythroid aplasia. Blood 30:587–600PubMed

50.

Dessypris EN, Redline S, Harris JW, Krantz SB (1985) Diphenylhydantoin-induced pure red cell aplasia. Blood 65:789–794PubMed

51.

Sugaya A, Nakamagoe K, Okoshi Y et al (2010) Diphenylhydantoin-induced severe yet reversible anemia during pregnancy. Intern Med 49:2515–2518PubMed

52.

Paul G, Sood P, Berry A, Paul BS (2011) Pure red cell aplasia with phenytoin following traumatic brain injury. Neurol India 59:69–70PubMed

53.

Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL (1983) Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood 61:889–893PubMed

54.

Blain H, Hamdan KA, Blain A, Jeandel C (2002) Aplastic anemia induced by phenytoin: a geriatric case with severe folic acid deficiency. JAGS 50:396–401

55.

Shalev O, Gilon D, Nubani NH (1987) Masked phenytoin-induced megaloblastic anemia in beta-thalassemia minor. Acta Haematol 77:186–187PubMed

56.

Menitove JE, Rassiga AL, McLaren GD et al (1981) Antigranulocyte antibodies and deranged immune function associated with phenytoin-induced serum sickness. Am J Hematol 10:277–284PubMed

57.

Rawanduzy A, Sarkis A, Rovit RL (1993) Severe phenytoin-induced bone marrow depression and agranulocytosis treated with human recombinant granulocyte-macrophage colony-stimulating factor. J Neurosurg 79:121–124PubMed

58.

Dahlke MB, Mertens-Roesler E (1967) Malabsorption of folic acid due to diphenylhydantoin. Blood 30:341–351PubMed

59.

Hawkins CF, Meynell MJ (1958) Macrocytosis and macrocytic anaemia caused by anticonvulsant drugs. Q Med J 27:45

60.

Kahn SB, Lischner H, Baker L, Williams WJ (1963) Megaloblastic anemia associated with the ingestion of phenobarbital and primidone. Report of a case in a six-year-old child. Pediatrics 32:376–383PubMed

61.

Sherwin AL, Wait RH, Cooper BA (1960) Megloblastic anaemia associated with phenobarbital therapy. Can Med Assoc J 82:368PubMedCentralPubMed

62.

Focosi D, Kast RE, Benedetti E et al (2008) Phenobarbital-associated bone marrow aplasia: a case report and review of the literature. Acta Haematol 119:18–21PubMed

63.

John K, Hermann J, Hässler A, John R (1980) Panmyelopathy in combined epilepsy therapy using ethosuccimide, diphenylhydantoin, and phenobarbital in childhood. Kinderarztl Prax 48:304–310PubMed

64.

Kojima S, Sasaki J, Tomita M et al (2009) Multiple organ toxicity, including hypochromic anemia, following repeated administration of PB in rats. J Toxicol Sci 34:527–539PubMed

65.

Khoutorsky A, Bruchim Y (2008) Transient leucopenia, thrombocytopenia and anaemia associated with severe acute phenobarbital intoxication in a dog. J Small Anim Pract 49:367–369PubMed

66.

Solomon GE, Hilgartner MW, Kutt H (1974) Phenobarbital-induced coagulation defects in cats. Neurology 24:920–924PubMed

67.

Ferguson PW, Anderson JH, Krieger RI (1979) Secondary thrombocytopenia following phenobarbital treatments in a rhesus monkey (Macaca mulatta). Lab Anim Sci 29:94–96PubMed

68.

Taliani U, Camellini A, Bernardi P et al (1989) A clinical case of severe megaloblastic anemia during treatment with primidone. Acta Biomed Ateneo Parmense 60:245–248PubMed

69.

Chanarin I, Elmes PC, Mollin DL (1958) Folic acid studies in megaloblastic anaemia due to primidone. Br Med J 2:80–82PubMedCentralPubMed

70.

Parker WA (1974) Primidone thrombocytopenia. Ann Intern Med 81:559–560PubMed

71.

Gerstner T, Teich M, Bell N et al (2006) Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 47:1136–1143PubMed

72.

Nasreddine W, Beydoun A (2008) Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 49:438–445PubMed

73.

Pohlmann-Eden B, Peters CNA, Wennberg R, Dempfle CE (2003) Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 108:142–145PubMed

74.

Teich M, Longin E, Dempfle CE, König S (2004) Factor XIII deficiency associated with valproate treatment. Epilepsia 45:187–189PubMed

75.

Kreuz W, Linde R, Funk M et al (1992) Valproate therapy induces von Willebrand disease type I. Epilepsia 33:178–184PubMed

76.

Gidal B, Spencer N, Maly M et al (1994) Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 44:1418–1422PubMed

77.

Gill JC, Endres-Brooks J, Bauer PJ et al (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691–1695PubMed

78.

König SA, Eiger CE, Vasella F (1999) Empfehlungen zur Blutuntersuchung und der klinischen Überwachung zur Früherkennung des Valproat-assoziierten Leberversagens. Mschr Kinderheilk 147:718–723

79.

Kreuz W, Mentzer D, Becker S et al (1994) Haemate P in children with von Willebrand’s disease. Haemostasis 24:304–310PubMed

80.

Eberl W, Budde U, Bentele K et al (2009) Acquired von Willebrand syndrome as side effect of valproic acid therapy in children is rare. Hämostaseologie 29:137–142PubMed

81.

Ünal Ö, Deda G, Teber S et al (2009) Thrombophilic risk factors in epileptic children treated with valproic acid. Pediatr Neurol 40:102–106PubMed

82.

Ugras M, Yakinci C (2006) Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate. Brain Dev 28:549–553PubMed

83.

Watts RG, Emanuel PD, Zuckerman KS, Howard TH (1990) Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis. J Pediatr 117:495–499PubMed

84.

Curnutte JT, Coates TD (2000) Disorders of phagocyte function and number. In: Hoffman R, Benz EJ Jr, Shattil SJ et al (eds) Hematology: basic principles and practice, 3rd edn. Churchill Livingstone, New York, pp 743–745

85.

Vesta KS, Medina PJ (2003) Valproic acid-induced neutropenia. Ann Pharmacother 37:819–821PubMed

86.

Suchitra A, James B (2000) Hematologic toxicity of sodium valproate. J Pediatr Hematol 22:62–65

87.

Kaufman DW, Kelly JP, Anderson T et al (1997) Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 38:1265–1269PubMed

88.

Ney GC, Schaul N, Loughlin J et al (1994) Thrombocytopenia in association with adjunctive felbamate use. Neurology 44:980–981PubMed

89.

Derbyshire E, Martin D (2004) Neutropenia occurring after starting gabapentin for neuropathic pain. Clin Oncol (R Coll Radiol) 16:575–576

90.

Kilbas S (2006) Lamotrigine-induced leucopenia. Epileptic Disord 8:317PubMed

91.

Okur M (2012) Lamotrigine-associated thrombocytopenia and leukopenia. J Emerg Med 42:584–587PubMed

92.

Sahaya K, Goyal MK, Sarwal A, Singh NN (2010) Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia 51:2492–2495PubMed

93.

Bauer J, Ben-Menachem E, Kramer G et al (2006) Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand 114:169–176PubMed

94.

De Smedt T, Raedt R, Vonck K et al (2007) Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 13:57–78PubMed

95.

Glauser TA, Pellock JM, Bebm EM et al (2002) Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43:518–524PubMed

96.

Gallerani M, Mari E, Boari B et al (2009) Pancytopenia associated with levetiracetam treatment. Clin Drug Investig 29:747–751PubMed

97.

Boon P, Hulhoven R, Offner F (2007) Levetiracetam and bleeding disorders. Acta Neurol Belg 107:97–102PubMed

98.

Elouni B, Ben Salem C, Biour M (2009) Levetiracetam-induced pancytopenia. Ann Pharmacother 43:985PubMed

99.

Hacquard M, Richard S, Lacour JC et al (2009) Levetiracetam-induced platelet dysfunction. Epilepsy Res 86:94–96PubMed

100.

Milia A, Pilia G, Mascia MG et al (2008) Oxcarbazepine-induced leukopenia. J Neuropsychiatry Clin Neurosci 20:502–503PubMed

101.

Mahmud J, Mathews M, Verma S, Basil B (2006) Oxcarbazepine-induced thrombocytopenia. Psychosomatics 47:73–74PubMed

102.

Hsiao YT, Wei IH, Huang CC (2010) Oxcarbazepine-related neutropenia: a case report. J Clin Psychopharmacol 30:94–95PubMed

103.

Calamaras MR, Stowe ZN, Newport DJ (2007) Pancytopenia associated with the introduction of oxcarbazepine. J Clin Psychopharmacol 27:217–218PubMed

104.

Chaudhry MM, Abrar M, Mutahir K, Mendoza C (2008) Oxcarbazepine-induced hemolytic anemia in a geriatric patient. Am J Ther 15:187–189PubMed

105.

Physician Desk Reference (2000) p. 2214, p. 2394

106.

Gerson SL, Lieberman JA, Friedenberg WR et al (1991) Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 338:262PubMed

107.

Behar D, Schaller JL (2004) Topiramate leukopenia on clozapine. Eur Child Adolesc Psychiatry 13:51–52PubMed

108.

Longin E, Teich M, Koelfen W, König S (2002) Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 43:451–454PubMed

109.

Tichelli A, Gratwohl A, Wursch A et al (1988) Late haematological complications in severe aplastic anaemia. Br J Haematol 69:413–418PubMed

110.

Palace J, Lang B (2000) Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry 69:711–714PubMedCentralPubMed

111.

Siniscalchi A, Gallelli L, Calabrò G et al (2010) Phenobarbital/lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy. Ann Pharmacother 44:2031–2034PubMed

Title: Anticonvulsant drugs and hematological disease
Authors: A. Verrotti
A. Scaparrotta
S. Grosso
F. Chiarelli
G. Coppola
Publication date: 01-07-2014
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 7/2014
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-014-1701-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anticonvulsant drugs and hematological disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2014

Quality of life in patients with craniocervical dystonia: Italian validation of the “Cervical Dystonia Impact Profile (CDIP-58)” and the “Craniocervical Dystonia Questionnaire (CDQ-24)”

Transient aphasia: a rare complication of head-up tilt test

Highlights of the Issue 7, 2014

Multiple dysgenesis of brain supplying arteries in a patient with osteogenesis imperfecta

Flavonoid, morin inhibits oxidative stress, inflammation and enhances neurotrophic support in the brain of streptozotocin-induced diabetic rats

Diabetes and the brain: issues and unmet needs